Houston, Texas, April 13, 2023 (GLOBE NEWSWIRE) — You may have heard the motto, “Those who dare to teach must never cease to learn.” This principle strongly applies to two Houston-area educators who, through Centro Semillero at University of St. Thomas-Houston (UST), have confirmed their callings as teachers and fortified
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $3 Million from its At-the-Market Equity Offering Mont-Saint-Guibert, Belgium – April 13, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea
Omnichannel-first companies are seeing a growth multiplier effect 2x that of their peers NEW YORK and LONDON, April 13, 2023 (GLOBE NEWSWIRE) — McKinsey & Company’s latest Global B2B Pulse reveals that market share winners are going all in on omnichannel, even in uncertain times. In particular, companies that reported
KUALA LUMPUR, Malaysia, April 13, 2023 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) announced that its ordinary shares have commenced trading on The Nasdaq Capital Market today under the ticker symbol “VCIG.” On April 13, 2023, the Company priced its firm commitment underwritten public
KUALA LUMPUR, Malaysia, April 13, 2023 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) today announced the pricing of its initial public offering of 1,280,000 shares of its ordinary shares at a price to the public of $4.00 per share for a total of $5,120,000
Edison App MILAN, Italy, April 13, 2023 (GLOBE NEWSWIRE) — The My Edison App by Edison Energia, an Edison Group company active in the sale of electricity and gas and services to families and businesses, was voted Product of the Year in the ‘Energy Services’ category at the 2023 edition
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis Funds will support the Phase I/II clinical development of Alentis’ two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors, and CLDN1 platform development After its
